192 related articles for article (PubMed ID: 18675682)
1. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
Roden M
Lancet; 2008 Aug; 372(9636):371; author reply 372. PubMed ID: 18675682
[No Abstract] [Full Text] [Related]
2. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
Arnolds S; Rave K
Lancet; 2008 Aug; 372(9636):370-1; author reply 372. PubMed ID: 18675680
[No Abstract] [Full Text] [Related]
3. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
Oliveira JH; Kazda C; Simpson A; Jackson JA; Heine RJ
Lancet; 2008 Aug; 372(9636):371-2; author reply 372. PubMed ID: 18675683
[No Abstract] [Full Text] [Related]
4. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
[TBL] [Abstract][Full Text] [Related]
5. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients.
Hirsch IB; Yuan H; Campaigne BN; Tan MH
Endocr Pract; 2009; 15(4):343-8. PubMed ID: 19454394
[TBL] [Abstract][Full Text] [Related]
6. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
[TBL] [Abstract][Full Text] [Related]
7. Insulin glargine clinical trials.
White JR
Clin Ther; 2004 Jul; 26(7):1179-81; discussion 1182-3. PubMed ID: 15336483
[No Abstract] [Full Text] [Related]
8. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
9. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
10. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
11. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
[TBL] [Abstract][Full Text] [Related]
13. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
Buse JB; Wolffenbuttel BH; Herman WH; Shemonsky NK; Jiang HH; Fahrbach JL; Scism-Bacon JL; Martin SA
Diabetes Care; 2009 Jun; 32(6):1007-13. PubMed ID: 19336625
[TBL] [Abstract][Full Text] [Related]
14. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
[TBL] [Abstract][Full Text] [Related]
15. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
Rosenstock J; Nino A; Soffer J; Erskine L; Acusta A; Dole J; Carr MC; Mallory J; Home P
Diabetes Care; 2020 Oct; 43(10):2509-2518. PubMed ID: 32694215
[TBL] [Abstract][Full Text] [Related]
16. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents.
Wolffenbuttel BH; Klaff LJ; Bhushan R; Fahrbach JL; Jiang H; Martin S
Diabet Med; 2009 Nov; 26(11):1147-55. PubMed ID: 19929994
[TBL] [Abstract][Full Text] [Related]
17. Starting insulin therapy in type 2 diabetes: lesson 1.
McCall AL
Curr Diab Rep; 2005 Oct; 5(5):325-6. PubMed ID: 16188164
[No Abstract] [Full Text] [Related]
18. [Start of insulin therapy. How to ensure patient compliance?].
MMW Fortschr Med; 2006 Aug; 148(35-36):12-3. PubMed ID: 16995354
[No Abstract] [Full Text] [Related]
19. Re: trial comparing insulin detemir with insulin glargine.
Swinnen S; Holleman F
Clin Ther; 2009 May; 31(5):1124-5; author reply 1125-6. PubMed ID: 19539113
[No Abstract] [Full Text] [Related]
20. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
